A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Astra goes early in small cell
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
Interview – Coherus sees the stars aligning at last
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.
